Introducing Ritonavir-Boosted Nirmatrelvir (Paxlovid) at the National Center for Global Health and Medicine: Surveys Following its Introduction

  • SHIGENO Ayako
    Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine
  • OHASHI Yasukata
    Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine
  • MASUI Ryosuke
    Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine
  • KIRYU Ayako
    Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine
  • NAGASHIMA Koji
    Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine
  • OHASHI Hirotake
    Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine
  • SETO Keisuke
    Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine
  • MASUDA Junichi
    Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine
  • TERUYA Katsuji
    AIDS Clinical Center, Center Hospital of the National Center for Global Health and Medicine
  • UJIIE Mugen
    Disease Control and Prevention Center, Center Hospital of the National Center for Global Health and Medicine
  • OHMAGARI Norio
    Disease Control and Prevention Center, Center Hospital of the National Center for Global Health and Medicine
  • NISHIMURA Takahiro
    Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine

Bibliographic Information

Other Title
  • 国立国際医療研究センター病院におけるニルマトレルビル/リトナビル導入に向けた取り組みと導入後の実態調査

Search this article

Description

<p>Background: Paxlovid, an oral COVID-19 drug, is a ritonavir-containing drug, and as it significantly affects the activities of various drug-metabolizing enzymes, drug-drug interactions (DDIs) are a significant concern during clinical use of the drug. However, there are few reports on the observations during actual clinical use of Paxlovid.</p><p>Methods: We developed a list of drugs that should only be used with caution along with Paxlovid and used a DDI search tool to easily check for DDIs during use of Paxlovid. We also investigated the number of inquiries about DDIs, the number of suggestions made by pharmacists, and the number of suggestions adopted by physicians in the 33 patients prescribed with Paxlovid during the 3-month period from February 15, 2022, to May 14, 2022. In addition, as part of the patient follow-up conducted after the start of Paxlovid, outpatients who were on medications that needed to be temporarily discontinued during Paxlovid use were contacted by telephone to confirm their medication adherence/medication discontinuation compliance status and the timing of resumption of the temporarily discontinued medications.</p><p>Results: There were 28 inquiries regarding DDIs, and the adoption rate of the pharmacists' suggestions by the treating physicians was 100%. One out of the seven patients who we contacted by telephone did not clearly understand the correct timing for resuming the temporarily discontinued medications. The pharmacist gave instruction again to the patient over the phone and subsequently confirmed, in a follow-up phone call, that the medication had been resumed without error.</p><p>Discussion: Pharmacists can contribute to the proper use of Paxlovid and reduce barriers to prescribing Paxlovid through management of DDIs and patient follow-up.</p>

Journal

  • Kansenshogaku Zasshi

    Kansenshogaku Zasshi 97 (4), 125-135, 2023-07-20

    The Japanese Association for Infectious Diseases

References(10)*help

See more

Details 詳細情報について

Report a problem

Back to top